Celera Corporation Separates from Applera Corporation.Celera Stock Expected to Start Trading as CRA See Community Reinvestment Act. on NASDAQ NASDAQ in full National Association of Securities Dealers Automated Quotations U.S. market for over-the-counter securities. Established in 1971 by the National Association of Securities Dealers (NASD), NASDAQ is an automated quotation system that reports on Today William G. Green Elected Non-Executive Chairman of the Board of Directors ALAMEDA, Calif. -- Celera Corporation (NASDAQ:CRA) today announced that it has completed its separation from Applera Corporation, and as an independent publicly traded company publicly traded company A company whose shares of common stock are held by the public and are available for purchase by investors. The shares of publicly traded firms are bought and sold on the organized exchanges or in the over-the-counter market. now holds the businesses, assets and liabilities previously attributed to the Celera Group. The company's shares are expected to be listed on the Nasdaq Stock Market Nasdaq stock market The first electronic stock market listing over 5000 companies. The Nasdaq stock market comprises two separate markets, namely the Nasdaq National Market, which trades large, active securities and the Nasdaq Smallcap Market that trades emerging growth companies. when trading opens today at 9:30 a.m. E.D.T., under the ticker symbol Ticker Symbol An arrangement of characters (usually letters) representing a particular security listed on an exchange or otherwise traded publicly. When a company issues securities to the public marketplace, it selects an available ticker symbol for its securities which investors , CRA. "It's a new day for Celera as we emerge as an independent healthcare company focused on personalizing disease management," said Kathy OrdoSez, Chief Executive Officer and President of Celera. "Our employees and our newly formed Board of Directors are energized about working together to build a successful future for our growing business, with its promising pipeline of new products and strong balance sheet." The following individuals were previously named Directors for Celera: * Richard H. Ayers, retired Chairman and Chief Executive Officer of The Stanley Works, a tool and hardware manufacturer, and previously a director of Applera Corporation; * Jean-Luc Belingard, Chairman and Chief Executive Officer of Ipsen S.A., a diversified French healthcare company, and previously a director of Applera Corporation; * Kathy OrdoSez, Chief Executive Officer and President of Celera and previously President of the Celera Group and founder of Celera Diagnostics; and * Bennett M. Shapiro, M.D., a director of PureTech Ventures, a venture capital firm specializing in investments in novel therapeutics, medical devices, and research technologies, and previously an Executive Vice President of Merck & Co., Inc. They are joined today by two additional Directors: * William G. Green, General Counsel and Chief Program Officer of the Gordon and Betty Moore Foundation Gordon and Betty Moore Foundation, private philanthropic organization established in 2000 by Gordon Moore, co-founder of Intel Corp., and his wife Betty. The foundation funds projects in science and environmental conservation as well as programs in and around San , a private philanthropic foundation Noun 1. philanthropic foundation - a foundation that provides funds for science or art or education or religion or relief from disease etc. charity - a foundation created to promote the public good (not for assistance to any particular individuals) , and previously Senior Vice President, General Counsel and Secretary of Chiron Corporation Chiron Corporation was a multinational biotechnology firm based in Emeryville, California that was acquired by Novartis International AG on April 20 2006. It had offices and facilities in eighteen countries on five continents. , a biotechnology company; and * Gail K. Naughton, Ph.D., Dean of the College of Business Administration at San Diego State University San Diego State University (SDSU), founded in 1897 as San Diego Normal School, is the largest and oldest higher education facility in the greater San Diego area (generally the City and County of San Diego), and is part of the California State University system. and Chairman and Chief Executive Officer of Histogen, Inc., a regenerative medicine company. The new Celera Board of Directors has elected William G. Green as its non-executive Chairman. Celera's Board of Directors intends to align Celera's fiscal year with the calendar year. As part of this process, Celera expects to issue its outlook for the remaining six months of calendar 2008 when it reports earnings for the fiscal year ended June 30, 2008. Ms. OrdoSez added, "Celera has built the foundation necessary to deliver on its mission of personalizing disease management. At Berkeley HeartLab, for example, we're developing new tests that are based on Celera's discoveries. One of the first among these is a testing service for a gene variant called KIF6, which has been associated with risk for heart disease and statin stat·in n. Any of a class of drugs that inhibit a key enzyme involved in the synthesis of cholesterol and promote receptor binding of LDL cholesterol, resulting in decreased levels of serum cholesterol. benefit. We're very encouraged by the response to the KIF6 test in our ongoing trial market at BHL BHL Bleeding-Heart Liberal BHL Battle Handover Line BHL Breath Hydrogen Level BHL Biohazard Level BHL Bottom of Heated Length BHL Bachelor of Hebrew Letters/Literature BHL Bilateral Hilar Lymphadenomegaly BHL Back-Hoe Loader and look forward to the national launch of the test in the coming weeks." "We are delighted to welcome Celera, one of today's most innovative healthcare companies, to the NASDAQ OMX OMX Office Max (stock symbol) family," said Bob Greifeld, Chief Executive Officer, NASDAQ OMX Group NASDAQ OMX Group is the tentative name for the combined entity resulting from the pending merger of The NASDAQ Stock Market, Inc. and OMX AB. Its headquarters will be located in New York. , Inc. "As the world's largest exchange company and home to the biotech industry, we are thrilled to have Celera join our 3,900 listed companies." This morning, Celera also launched its new website aimed at communicating the core focus of the company and providing updates regarding its key business segments. Please visit http://www.celera.com for more information. About Celera Celera is a healthcare business delivering personalized disease management through a combination of products and services incorporating proprietary discoveries. Berkeley HeartLab, a subsidiary of Celera, offers services to predict cardiovascular disease Cardiovascular disease Disease that affects the heart and blood vessels. Mentioned in: Lipoproteins Test cardiovascular disease risk and optimize patient management. Celera also commercializes a wide range of molecular diagnostic products through its strategic alliance with Abbott and has licensed other relevant diagnostic technologies developed to provide personalized disease management in cancer and liver diseases. Information about Celera Corporation, including reports and other information filed by the company with the Securities and Exchange Commission, is available at http://www.celera.com. Forward-Looking Statements Some statements contained in, or incorporated by reference in, this press release are forward-looking and are subject to a variety of risks and uncertainties. These forward-looking statements may be identified by the use of forward-looking words or phrases such as "believe," "expect," "intend," and "anticipate," among others. The forward-looking statements contained in this press release are based on our current expectations, and those made at other times will be based on our expectations when the statements are made. We cannot guarantee that any forward-looking statements will be realized. The Private Securities Litigation Reform Act The Private Securities Litigation Reform Act of 1995 (PSLRA) implemented several significant substantive changes affecting certain cases brought under the federal securities laws, including changes related to pleading, discovery, liability, class representation and awards fees and of 1995 provides a "safe harbor Safe Harbor 1. A legal provision to reduce or eliminate liability as long as good faith is demonstrated. 2. A form of shark repellent implemented by a target company acquiring a business that is so poorly regulated that the target itself is less attractive. " for forward-looking statements. To comply with the terms of the safe harbor, we note that a variety of factors could cause actual results and experience to differ materially from anticipated results or other expectations expressed in forward-looking statements. We also note that achievement of anticipated results or expectations in forward-looking statements is subject to the possibility that assumptions underlying forward-looking statements will prove to be inaccurate. Investors should bear this in mind as they consider forward-looking statements. The risks and uncertainties that may affect the operations, performance, development, and results of our business include, but are not limited to, those described under the heading "Risks Factors" our Registration Statement on form S-1 declared effective by the Securities and Exchange Commission on June 19, 2008. We note that our business could be affected by other factors that we have not disclosed because we think they are immaterial. Also, there may be additional risks and uncertainties that could affect our businesses but which are not currently known to us. Copyright[c] 2008. Celera Corporation. All Rights Reserved. Celera is a registered trademark of Celera Corporation or its subsidiaries in the U. S. and/or certain other countries. |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion